FINWIRES · TerminalLIVE
FINWIRES

Update: Dyno Nobel Posts Higher Fiscal H1 Adjusted Earnings, Lower Revenue; Shares Hit Three-Year High

By

-- (Updates to add stock movement in the headline and last paragraph)

Dyno Nobel (ASX:DNL) reported Monday fiscal first-half earnings of AU$0.089 per share, excluding individually material items, up from AU$0.046 a year earlier.

Analysts polled by FactSet expected earnings of AU$0.07.

Revenue from ordinary activities for the six months ended March 31 was AU$1.9 billion, compared with AU$2.25 billion a year earlier. Analysts surveyed by FactSet expected AU$1.78 billion.

The company maintained its fiscal 2026 earnings before interest and taxes guidance at around AU$460 million to AU$500 million while lowering capital expenditure guidance to AU$250 million to AU$300 million due to the deferral of some growth-related spending into fiscal 2027.

The board declared an interim dividend of AU$0.046 per share, up from AU$0.024 a year earlier, payable July 2 to shareholders on record as of June 15.

The company's shares rose 9% in recent Monday trade and earlier hit their highest since January 2023.

Related Articles

Asia

Shenzhen LDROBOT Soars 103% in Hong Kong Trading Debut

Shenzhen LDROBOT's (HKG:1236) shares opened 102.9% above their initial public offering price in a stellar Hong Kong debut on Monday morning.The Chinese robotics company opened at HK$53.50 per share, well above the offer price of HK$26.36.

$HKG:1236
Asia

Concord Healthcare to Issue HK$68 Million Convertible Bonds to CSPC Pharma Unit

Concord Healthcare (HKG:2453) agreed to issue HK$68 million of convertible bonds to a unit of CSPC Pharmaceutical (HKG:1093), according to a Monday Hong Kong bourse filing.The oncology healthcare service provider said Dragon Merit will subscribe to the 2% convertible bonds due in April 2027.The bonds are convertible into as many as 40 million Hong Kong-listed shares at an initial conversion price of HK$1.70 per share, representing a premium of about 14.1% to the stock's last closing price.Net proceeds of about HK$63.1 million will mainly be used to repay loans and supplement working capital.Concord Healthcare said the investment is expected to deepen cooperation with CSPC Pharmaceutical in the oncology healthcare sector.

$HKG:1093$HKG:2453
Asia

Alterity Therapeutics Says Peer-Reviewed Study Validates its Approach to Multiple System Atrophy; Shares Fall 9%

Alterity Therapeutics (ASX:ATH) said findings of a study published in the NeuroImage journal support quantitative susceptibility mapping as an objective imaging biomarker to facilitate the earlier diagnosis of multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.Alterity is advancing its ATH434 lead candidate into a phase three program for multiple system atrophy, a neurodegenerative disease that leads to the failure of the autonomic nervous system and impaired movement.The company said it used quantitative susceptibility mapping in a phase two trial in which ATH434 helped improve diagnostic accuracy and provided "objective evidence of target engagement."The peer-reviewed publication validates the company's approach and "reinforces the role of [quantitative susceptibility mapping] as a biomarker for iron-modulating therapies in MSA," Alterity CEO David Stamler said.The company's shares fell 9% in recent Monday trade.

$ASX:ATH